BEVC is thrilled to support Montara Therapeutics, Inc. as the team pushes forward with the BrainOnly? platform to advance much-needed neurological treatments.
?? I’m excited to share that Montara Therapeutics, Inc. has raised an additional $20M in an oversubscribed seed expansion round, bringing our total funding to $28M, along with significant non-dilutive grant support, to advance our BrainOnly? therapies. This investment allows us to continue executing at a rapid pace, developing safer, more effective neurological treatments with our BrainOnly? platform. ?? With this funding, we are: ?? Advancing our lead epilepsy program toward IND submission within the next year ?? Progressing our neurodegeneration program toward a development candidate ?? Expanding our pipeline with a third, undisclosed program leveraging BrainOnly? technology The current market has been tough, particularly for platform biotech companies, as investors prioritize near-term value creation. We took a disciplined approach—advancing a lead epilepsy program rapidly toward IND while developing the BrainOnly? platform in parallel. This ensures we’re not just building long-term innovation, but also creating a high-value clinical asset, which made Montara an attractive investment. We are fortunate to have the continued support of SV Health Investors' Dementia Discovery Fund (DDF), Two Bear Capital, Dolby Family Ventures, and KdT Ventures, along with new investors BEVC and others. I’m also pleased to welcome ???? Troy Wilson as Chairman of the Board, whose experience in building and scaling biotech companies will be invaluable as we move toward the clinic. More to come on this development! ?? Read the full announcement here: https://lnkd.in/gc536sSr And a special ?? thank you to my wife, Janel Molton Hertz, for always supporting me through this journey. #biotech ?? #CNS ?? #drugdevelopment ?? #BrainOnly #MontaraTherapeutics